secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001599298-24-000089
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics enters $90M ATM equity distribution agreement with JPMorgan
-------------------------------------------------------------------------------

- Up to $90M of common stock may be sold at-the-market through J.P. Morgan Securities LLC as sales agent.
- Company has no obligation to sell any shares; sales at prevailing market prices or negotiated prices.
- Sales agent commission is up to 3.0% of gross proceeds per share sold.
- Offerings made under existing S-3 shelf registration (File No. 333-277169) declared effective Feb 27, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000089/0001599298-24-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000089/smmt-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer